Related Experiment Video

Updated: Aug 30, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.1K

Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection

Mirjana Kovac1, Gorana Mitic2, Marija Milenkovic3

  • 1Faculty of Medicine, University of Belgrade, Serbia; Blood Transfusion Institute of Serbia, Hemostasis Department, Belgrade, Serbia.

Thrombosis Research
|September 2, 2022
PubMed

Insights

Congenital thrombophilia did not increase COVID-19 thrombosis risk in this study. However, patients with thrombophilia may still benefit from tailored anticoagulant prophylaxis due to potential risks.

Area of Science:

  • Cardiology
  • Hematology
  • Infectious Diseases

Background:

  • COVID-19 infection can cause coagulation dysfunction and severe thrombotic complications.
  • Comorbidities and age are known risk factors for thrombosis in COVID-19 patients.
  • Limited data exists on the association between congenital thrombophilia and COVID-19-related thrombotic events.

Purpose of the Study:

  • To investigate the risk of COVID-19-associated thrombosis in patients with congenital thrombophilia.
  • To evaluate if congenital thrombophilia influences the occurrence or characteristics of thrombotic events post-COVID-19.

Main Methods:

  • Prospective case-control study of 90 COVID-19 patients (30 with congenital thrombophilia, 60 without).
  • Follow-up for 6 months post-COVID-19 diagnosis, monitoring for symptomatic thrombotic events.
  • Assessment of hemostatic parameters, including Factor VIII (FVIII) activity and D-dimer levels, at 1, 3, and 6 months.

Main Results:

  • Symptomatic thrombotic events occurred in 23% of patients with thrombophilia and 20% without (P=0.715).
  • No significant differences were observed in thrombotic event localization, timing, or response to antithrombotic treatment between groups.
  • D-dimer levels were significantly higher in patients without thrombophilia.

Conclusions:

  • Congenital thrombophilia did not appear to elevate the risk of symptomatic thrombotic events in COVID-19 patients in this cohort.
  • Despite similar event rates, individualized anticoagulant prophylaxis is recommended for patients with congenital thrombophilia, tailored to their specific genetic defect.
Abstract

Keywords:
COVID-19 infectionCongenital thrombophiliaVenous thromboembolism risk

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.1K
In Vitro Thrombosis Test for Ventricular Assist Devices09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

755

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
861
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
29
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
19